Quinoline

Quinoline

SCHEMBL3872200

O=C(O)C(F)(F)F.c1ccc2ncccc2c1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
L3MBTL1 Q9Y468 4/20 0.48
PABPC1 P11940 1/20 0.45
UBE2N P61088 1/20 0.45
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MGAM O43451 2/20 0.43
CYP3A4 P08684 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
MCL1 Q07820 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.42
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
PLK1 P53350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL5874750 1.00 ALDH1A1 (0.63) ALDH1A1L3MBTL1PABPC1UBE2NMAPT
Quinoline SCHEMBL5527084 0.95 ALDH1A1 (0.57) ALDH1A1L3MBTL1PABPC1UBE2NMAPT
Trifluoroacetic Acid SCHEMBL22397327 0.88 L3MBTL1 (0.45) ALDH1A1L3MBTL1UBE2NMAPTSMN1; SMN2
Quinoline SCHEMBL5874587 0.87 ALDH1A1 (0.65) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL28970061 0.86 ALDH1A1 (0.71) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL5874493 0.86 ALDH1A1 (0.77) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL372690 0.86 ALDH1A1 (0.77) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL5283313 0.86 ALDH1A1 (0.77) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL5875384 0.84 ALDH1A1 (0.74) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1
Quinoline SCHEMBL5272119 0.84 ALDH1A1 (0.74) ALDH1A1PABPC1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors PFIZER INC. (US) 2022-04-26 US disclosed
CN-106536502-B The phenyl tetrahydro isoquinoline compound being substituted by heteroaryl 大正制药株式会社 2019-03-05 CN disclosed
CN-106536502-A Phenyl tetrahydroisoquinoline compound substituted with heteroaryl 大正制药株式会社 2017-03-22 CN disclosed
CN-102985411-B Imaging agents for detecting neurological disorders ELI LILLY AND CO. (US) 2016-02-10 CN disclosed
CN-104995191-A Tricyclic quinoline and quinoxaline derivatives ABBVIE DEUTSCHLAND 2015-10-21 CN disclosed
CN-101594866-B Topical formulations HELPERBY THERAPEUTICS LTD. (GB) 2014-10-22 CN disclosed
CN-101351203-B Application of pyrroloquinoline compound in killing clinically latent microorganisms HELPERBY THERAPEUTICS LTD 2013-12-04 CN disclosed
CN-102186851-B Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2013-06-12 CN disclosed
CN-102438660-A Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS 2012-05-02 CN disclosed
CN-102186851-A Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2011-09-14 CN disclosed
WO-2007054693-A1 USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LIMITED (GB) 2007-05-18 WO disclosed
CN-1910149-A Bronchodilatory compounds RESPIRATORIUS AB (SE) 2007-02-07 CN disclosed
CN-1897948-A Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO (US) 2007-01-17 CN disclosed
CN-1809360-A 4-anilino-quinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2006-07-26 CN disclosed
CN-1261099-C Tetrahydroquinoline derivatives AKZO NOBEL NV (NL) 2006-06-28 CN disclosed
CN-1764651-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-04-26 CN disclosed
CN-1529601-A Tetrahydroquinoline derivatives ��˹��ŵ�� 2004-09-15 CN disclosed
CN-1323307-A 1H-imidazopyridine derivatives HOKURIKU SEIYAKU (JP) 2001-11-21 CN disclosed
EP-1140946-A2 QUINOLINE DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2001-10-10 EP disclosed
WO-2000035919-A2 QUINOLINE DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors LRRK2, PARK7, BRCA1 ALDH1A1 1569/4885L3MBTL1 108/4885PABPC1 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.